Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q2 EPS by 13c, Revenues Miss

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of ($0.26), $0.13 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $32.81 million versus the consensus estimate of $37.7 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
• Pony AI (PONY) Reports Revenue Above Estimates